|
|
T2 Biosystems Reports Granting of Inducement Award
|
|
|
T2 Biosystems to Participate in the Gilmartin Group Emerging Growth Company Showcase
|
|
|
T2 Biosystems Praises CDC’s Actions Aimed at Optimizing U.S. Hospital Sepsis Programs
|
|
|
T2 Biosystems Regains Compliance with Nasdaq’s Market Value of Listed Securities Requirement
|
|
|
T2 Biosystems Announces Second Quarter 2023 Financial Results
|
|
|
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirements
|
|
|
T2 Biosystems to Attend Upcoming Investor Conferences
|
|
|
T2 Biosystems to Report Second Quarter 2023 Financial Results on August 7, 2023
|
|
|
T2 Biosystems Reports Granting of Inducement Award
|
|
|
T2 Biosystems Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test
|
